Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Regenerative Capacity of Macrophages for Remyelination.
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis.
Coactivation of Lower Limb Muscles during Gait in Patients with Multiple Sclerosis.
First use of alemtuzumab in balo concentric sclerosis: a case report.
The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS).
Alemtuzumab-induced elimination of HIV-1-infected immune cells.
Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO.
Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Babesia parasitemia rebound after red blood cell exchange.
Schwann Cell O-GlcNAc Glycosylation Is Required for Myelin Maintenance and Axon Integrity.
Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis.
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
Brain-derived neurotrophic and immunologic factors: beneficial effects of riboflavin on motor disability in murine model of multiple sclerosis.
Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Humoral response against host-mimetic homologous epitopes of Mycobacterium avium subsp. paratuberculosis in Japanese multiple sclerosis patients.
The role of the wnt canonical signaling in neurodegenerative diseases.
Pregnancy in the Setting of Multiple Sclerosis.
GSK3β Promotes the Differentiation of Oligodendrocyte Precursor Cells via β-Catenin-Mediated Transcriptional Regulation.
Meningeal Infiltration of the Spinal Cord by Non-Classically Activated B Cells is Associated with Chronic Disease Course in a Spontaneous B Cell-Dependent Model of CNS Autoimmune Disease.
Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.
Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
Walking fatigability in multiple sclerosis: A comparison between the 2- and the 6-minute walk test and an evaluation of associated factors.
When global rating of change contradicts observed change: Examining appraisal processes underlying paradoxical responses over time.
Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage.
Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding.
Pages
« first
‹ previous
…
770
771
772
773
774
775
776
777
778
…
next ›
last »